Chondrokin is an antibody fusion protein, which delivers the anabolic factor IGF-1 to damaged cartilage, promoting local repair and regeneration.
The product is administered by intra-articular injection. In preclinical studies, Chondrokin demonstrated selective and persistent accumulation at the site of disease.
Further proof-of-concept was obtained in a rat model of osteoarthritis, in which Chondrokin treatment resulted in significant cartilage protection.
The product is currently under pre-clinical investigation in a sheep model for the treatment of cartilage damage disorders, paving the way to future clinical applications for the treatment of cartilage defects and of osteoarthritis.